AG-181 / Agios Pharma - LARVOL DELTA

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Participants With Phenylketonuria (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Agios Pharmaceuticals, Inc.

New P1 trial • Metabolic Disorders • Phenylketonuria • Rare Diseases

AG181-C-001: Single and Multiple Ascending Dose Study and Food Effect Study for AG181 (clinicaltrials.gov) - P1 | N=112 | Recruiting | Sponsor: Agios Pharmaceuticals, Inc. | Trial completion date: Oct 2025 ➔ Mar 2026 | Trial primary completion date: Oct 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date

AG181-C-001: Single and Multiple Ascending Dose Study and Food Effect Study for AG181 (clinicaltrials.gov) - P1 | N=112 | Recruiting | Sponsor: Agios Pharmaceuticals, Inc. | Trial completion date: Jun 2025 ➔ Oct 2025 | Trial primary completion date: Jun 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date

AG181-C-001: A Safety Study of Single and Multiple Doses of AG-181 in Healthy Participants (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Agios Pharmaceuticals, Inc. | Trial completion date: Sep 2025 ➔ Jun 2025 | Trial primary completion date: Sep 2025 ➔ Jun 2025

Trial completion date • Trial primary completion date

AG181-C-001: Single and Multiple Ascending Dose Study and Pilot Food Effect Study for AG-181 (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Agios Pharmaceuticals, Inc.

New P1 trial